OneMedNet expands cardiovascular data network with 85 new centers

MINNEAPOLIS - OneMedNet Corporation (NASDAQ:ONMD), a micro-cap healthcare technology company with a market capitalization of $35.31 million, announced Wednesday it has added 85 cardiovascular centers and data sources to its network, positioning itself as one of the largest providers of cardiovascular real-world data. According to InvestingPro analysis, the company’s stock has shown significant momentum, surging over 58% in the past week.

The expansion enhances the company’s ability to deliver de-identified cardiovascular imaging, diagnostic reports, and electrocardiograms to life sciences companies, AI developers, and medical device manufacturers. While the company generated revenue of $0.46 million in the last twelve months, InvestingPro data reveals challenges with cash burn and profitability that investors should monitor.

"By combining de-identified cardiovascular imaging, structured reports, and ECG signals from this vast network, we’re providing real-world clinical insights that accelerate innovation in diagnostics, therapeutics, and AI model development," said Aaron Green, President and CEO of OneMedNet.

The company stated that cardiovascular diseases remain the world’s leading cause of death, responsible for approximately 19.8 million deaths in 2022, accounting for roughly 32% of all global mortality. The economic burden of cardiovascular disease is estimated at $320 billion annually in the United States and more than $1 trillion globally each year in direct healthcare costs and lost productivity.

OneMedNet’s platform connects to over 1,750 healthcare sites, providing access to de-identified medical imaging and electronic health records across various medical specialties including rare diseases, oncology, and cardiology.

The announcement comes as pharmaceutical companies and insurers seek more comprehensive real-world data to understand disease progression, treatment responses, and outcomes.

This information is based on a company press release statement. For deeper insights into OneMedNet’s financial health and growth prospects, InvestingPro subscribers have access to over 10 additional exclusive ProTips and comprehensive financial metrics.

In other recent news, OneMedNet Corporation has expanded its real-world data network to include over 121 million clinical exams through collaborations with more than 1,400 hospital and healthcare provider sites. This expansion has been facilitated by partnerships with major data marketplaces such as Amazon Data Exchange and HealthVerity. Additionally, OneMedNet has secured approximately $3.7 million through private placement transactions at $0.42 per share, exceeding Nasdaq’s minimum price requirements, with participation from some of the company’s founders and directors.

The company has also announced a partnership with Inka Health Corp., a subsidiary of Onco-Innovations Limited, to develop external control arms for cancer therapy trials. This collaboration will utilize OneMedNet’s patient data platform along with Inka Health’s SynoGraph platform to focus initially on the Keynote-189 trial of pembrolizumab in non-small cell lung cancer. Onco-Innovations stated that its subsidiary, Inka Health, will lead a data analytics initiative aimed at enhancing cancer therapy development through this partnership. These developments mark significant steps in OneMedNet’s efforts to strengthen its position in the healthcare data ecosystem.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.